Aerovate Therapeutics Stock Performance
| AVTE Stock | USD 2.58 0.15 6.17% |
On a scale of 0 to 100, Aerovate Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 0.4, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aerovate Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aerovate Therapeutics is expected to be smaller as well. Please check Aerovate Therapeutics' treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Aerovate Therapeutics' price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.17 | Five Day Return 2.38 | Year To Date Return (4.09) | Ten Year Return (88.70) | All Time Return (88.70) |
1 | Disposition of 503 shares by Gillies Hunter of Aerovate Therapeutics at 1.74 subject to Rule 16b-3 | 10/24/2024 |
2 | Shareholder Alert Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders | 10/31/2024 |
3 | HAREHOLDER ALERT The MA Class Action Firm Continues To Investigate Merger - AVTE, BCOV, ... | 12/23/2024 |
4 | Disposition of 2051 shares by George Eldridge of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 | 01/16/2025 |
| Begin Period Cash Flow | 22.4 M | |
| Free Cash Flow | -56.9 M |
Aerovate |
Aerovate Therapeutics Relative Risk vs. Return Landscape
If you would invest 234.00 in Aerovate Therapeutics on October 20, 2024 and sell it today you would earn a total of 24.00 from holding Aerovate Therapeutics or generate 10.26% return on investment over 90 days. Aerovate Therapeutics is currently generating 0.2063% in daily expected returns and assumes 3.208% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Aerovate, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aerovate Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aerovate Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aerovate Therapeutics, and traders can use it to determine the average amount a Aerovate Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0643
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AVTE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.21 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average Aerovate Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aerovate Therapeutics by adding it to a well-diversified portfolio.
Aerovate Therapeutics Fundamentals Growth
Aerovate Stock prices reflect investors' perceptions of the future prospects and financial health of Aerovate Therapeutics, and Aerovate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aerovate Stock performance.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (13.6 M) | ||||
| Shares Outstanding | 28.91 M | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.93 X | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash And Equivalents | 151.99 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 675 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.85 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (56.78 M) | ||||
| Earnings Per Share | (3.17) X | ||||
| Market Capitalization | 74.59 M | ||||
| Total Asset | 127.42 M | ||||
| Retained Earnings | (163.42 M) | ||||
| Working Capital | 106.59 M | ||||
About Aerovate Therapeutics Performance
By analyzing Aerovate Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Aerovate Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aerovate Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aerovate Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.56) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.79) | (0.75) |
Things to note about Aerovate Therapeutics performance evaluation
Checking the ongoing alerts about Aerovate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aerovate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aerovate Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Disposition of 2051 shares by George Eldridge of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 |
- Analyzing Aerovate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aerovate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aerovate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aerovate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aerovate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aerovate Therapeutics' stock. These opinions can provide insight into Aerovate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |